Deutsches Krebsforschungszentrum

Ruprecht-Karls-Universitat Heidelberg

Basilea Pharmaceutica Ag

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Ruprecht-Karls-Universitaet Heidelberg

Iomx Therapeutics Ag

Michael Boutros

Daniel Gilbert

Philipp Beckhove

Sandra Steinbrink

Florian Fuchs

Rajendra-Prasad Maskey

Marco Breinig

Corinna Koch

Felix Bachmann

Heidi Alexandra Lane

Xian Zhang

Nisit Khandelwal

Madlaina Breuleux

Sebastian Meier-ewert

Peter Sennhenn

Valentina Volpin

Ayse Nur Menevse

Antonio Sorrentino

Tillmann Michels

Iris Augustin

The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.

Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof

The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.

Cytotoxic T cell response modifiers

Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I). 

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

Compounds of formula (IIc); wherein Xand Xindependently from each other are N or CRwherein Rmay be same or different; Y, Y, Yand Yindependently from each other are N or CRwherein Rmay be same or different and wherein up to 3 of the group Y, Y, Yand Ymay be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer. 

Chromene derivatives and their analogs as Wnt pathway antagonists

Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a compound of general formula I wherein

Chromene derivatives and their analoga as Wnt pathway antagonists

The present invention relates to modulators of G protein-coupled receptor 177 (Gpr177) for use in the treatment, alleviation, prevention and/or diagnosis of cancer as well as to methods for the diagnosis of such cancer.

Gpr177 as target and marker in tumors

The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer. 

Tricyclic pyrimidine derivatives as wnt antagonists

Growing community of inventors

Heidelberg, Germany

Michael Boutros